In the latest quarter, 11 analysts provided ratings for Nevro (NYSE:NVRO), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Not only does Nevro’s system operate at a significantly higher frequency than many of its competitors’ spinal cord stimulators, but the company also claims that the HFZ approach eliminates the ...

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...

Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...

Investors panicked sending shares of Nevro Corp. plummeting by about one-third on July 24 from about $60 to less than $40 as they sought to understand the implications of the latest news in ongoing ...

New 18-month data for a 10-kHz implanted spinal cord stimulation device (Nevro) shows continued relief of painful diabetic neuropathy symptoms in patients refractory to conventional medical therapy.

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised its 2024 adjusted EBITDA loss guidance to $18 million-$16 million from its ...

Nevro today announced that it received two patents for its Senza High-Frequency Spinal Cord Stimulation System, a device aimed at patients with chronic pain. The first patent concerns the device’s ...